Australian medical device company OncoSil Medical (ASX:OSL) has announced that the first patient has been treated in the PANCOSIL Investigator-Initiated Clinical Trial.
The trial is examining the safety and feasibility of the OncoSil device utilising percutaneous application for patients with locally advanced pancreatic cancer. In the trial, 20 patients will be treated with the OncoSil device and the aim is to assess the safety of percutaneous application.
According to Professor Doctor Martijn Meijerink, “I am very excited that today we have been able to treat the first patient with OncoSil through a CT‐guided percutaneous implantation procedure. This novel means of implantation of the OncoSil™ device has a number of potential advantages, such as the ability to more precisely place the radioactive microparticles within the pancreatic tumour in a simpler procedure, which can be performed by interventional radiologists many of whom are used to working with radionuclide therapies in the treatment of various malignant diseases.”
OncoSil Medical CEO and managing director Nigel Lange added, “We are excited by news that the first patient has been treated in the PANCOSIL study. The recruitment of patients to this study represents another significant milestone in our efforts to commercialise the OncoSil device. We expect the results of the study will help us to develop an alternative technique for OncoSil™ implantation and provide flexibility for users. This and other outcomes emerging from the PANCOSIL study will open the way for an increased number of medical professionals to deliver the OncoSil device to patients with locally advanced pancreatic cancer.”